Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Aug 22:2022:5404913.
doi: 10.1155/2022/5404913. eCollection 2022.

Pityriasis Versicolor Resistant to Antifungal Drugs in a Patient in Lomé (Togo)

Julienne Teclessou  1 , Koussake Kombate  1 , Bayaki Saka  2 , Séfako Abla Akakpo  2 , Palokinam Pitche  2
Affiliations
Case Reports

Pityriasis Versicolor Resistant to Antifungal Drugs in a Patient in Lomé (Togo)

Julienne Teclessou et al. Case Rep Dermatol Med. .

Abstract

Background: Pityriasis versicolor (PV) is a ubiquitous superficial skin mycosis that often affects young adults. It is often effectively treated with local or oral antifungal agents. Cases of PV resistance to antifungal agents have been reported rarely. We report a case of antifungal resistant PV. Observation. A 22-year-old patient was followed since the age of 17 years in a dermatology outpatient clinic for hyperpigmented scaly macular lesions of the trunk and upper limbs. The clinical diagnosis of PV was retained. The patient was treated by fluconazole 300 mg/week before being lost to follow-up. He was seen again in 2019 (about 2 years later) for the same symptomatology and treated again by fluconazole and ciclopirox olamine cream without improvement. He was again lost to follow-up and seen again six months later. A mycological sample was taken and Aspergillus niger was isolated. The patient was treated by itraconazole for 6 weeks. The evolution was marked by a clinical status quo. The patient was again put on salicylated petroleum jelly 10% associated with terbinafine cream and then lost to follow-up.

Conclusion: The emergence of fungal resistance to antifungal drugs does not spare PV. It can therefore be resistant to several antifungal drugs, leaving clinicians and patients in despair.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Scaly hypopigmented macular lesions of the trunk (months after the start of the second treatment).
Figure 2
Figure 2
Pityriasis versicolor (six weeks after itraconazole treatment).
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Szepietowski J. C., Baran E., Wild E. Tinea versicolor: a prospective study. Korean journal of medical mycology . 2000;5:108–112.
    1. Schwartz R. A. Superficial fungal infections. The Lancet . 2004;364(9440):1173–1182. doi: 10.1016/s0140-6736(04)17107-9. - DOI - PubMed
    1. Gupta A. K., Batra R., Bluhm R., Faergemann J. Pityriasis versicolor. Dermatologic Clinics . 2003;21(3):413–429. doi: 10.1016/s0733-8635(03)00039-1. - DOI - PubMed
    1. El Euch D., Riahi I., Mokni M., Ben Osman A., Mezlini S., Abidi H. [Ketoconazole foaming gel in tinea versicolor (report of 60 cases)] Tunisie Medicale . 1999;77(1):38–40. - PubMed
    1. Faergemann J. The role of Malassezia yeasts in skin diseases. Mikologia Lekarska . 2004;11:129–133.

Publication types

LinkOut - more resources